Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Subsea 7 S.A. Announces Fourth Quarter and Full Year 2025 Results
-
Banqup delivers on its growth ambition for FY 2025
-
Odysseus Holdings and CoinShares publish the offer document for the transaction with Vine Hill
-
Pulselight to host senior health leaders for panel on ‘efficiency drive’ to reduce NHS waste and duplication
-
NBPE Announces Transaction in Own Shares
-
Asahi Kasei to Acquire Aicuris to Accelerate Growth in Severe Infectious Diseases
-
OSB GROUP PLC - Transaction in Own Shares
-
valantic FSA appoints Christian K. Schwarz as Managing Director for Payments
-
Director Declaration
-
Transaction in Own Shares
-
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
-
INTERIM CONSOLIDATED REPORT FOR THE FOURTH QUARTER AND 12 MONTHS OF 2025 (UNAUDITED)
-
Rait Riim appointed as the new CEO of Arco Vara AS
-
HEINEKEN appoints new Chief Digital & Technology Officer
-
Reminder of an Investor Conference Webinar
-
Technip Energies Full Year 2025 Financial Results
-
Bouygues: Very robust 2025 results and free cash flow at a record level
-
Azerion publishes Interim Unaudited Financial Results Q4 2025 and Preliminary Unaudited Financial Results Full Year 2025
-
TCM Group A/S: Annual Report 2025
-
Aalberts N.V.: Aalberts reports full year results 2025
-
Bekaert announces the next tranche of its Share Buyback Program
-
Stigmare Announces New Client Ballard Box Worx, a North Texas Builder of Container-Based Job Site Offices Engineered for Extreme Heat
-
Alm. Brand A/S - Annual Report 2025
-
Phonak ambassadors spotlight hearing health for the next generation on World Hearing Day
-
CMB.TECH ANNOUNCES Q4 2025 RESULTS - EIGHT VLCCS SOLD AT STELLAR PRICES
-
SBM Offshore Full Year 2025 Earnings
-
WENDEL: 2025 Full-Year Results
-
Prosafe SE: Fourth-quarter results 2025
-
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
-
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
-
Syensqo fourth quarter and full year 2025 results
-
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
-
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
-
Start of Day Message
-
Sequana Medical Reports Strong US Commercial Progress with Five Centers Completing alfapump® System Implants Since Launch
-
AS Tallinna Sadam unaudited financial results for the year 2025 and Q4
-
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
-
Corbion announces strong full-year 2025 results with +26.7% organic Adjusted EBITDA growth, +63.3% EPS growth, and €90.8 million in FCF; announces special dividend
-
Planisware: Strong 2025 performance with renewed commercial momentum at year-end
-
Full-year results 2025: record performance marks 150 years of delivery
-
Clariant delivers third year of strong EBITDA margin improvement – EBITDA margin before exceptional items up 180 basis points versus prior year to 17.8 %
-
Expansion of the elderly care home “Tartu Südamekodu” in Tartu County
-
Bekaert: 2025 Full Year Results
-
dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program
-
THC Gummies: Budpop Ranked #1 by Sarasota Magazine for Premium THC Edibles
-
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
-
Annual Results 2025: clear second half improvement, restructuring measures show first results
-
Inbank unaudited financial results for Q4 and 12 months of 2025
-
Codetta Bio Announces Commercial Availability of Concerto™ System and New Customizable Cytokine and Neuroscience Panels at AGBT 2026
-
SolCex Enters Major Expansion Phase Following Two Years of Secure, Continuous Operation
